Similarly, if CDK2 drives proliferation of luminal breast cancers that have acquired resistance to CDK4/6 inhibition, it is not clear whether this reflects a change to a state of primary CDK2 dependence, or whether combined inhibition of CDK2 and CDK4/6 is needed to regain control of tumor cell proliferation. This evidence concerns the gene CDK4 and breast carcinoma.